Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00485277 · ClinicalTrials.gov registry record · Phase 1
A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer
A Phase 1 study of Breast Cancer, sponsored by Bavarian Nordic.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 2
- Study locations
NCT00485277: Completed Phase 1 study of Breast Cancer, sponsored by Bavarian Nordic.
NCT00485277 is a Phase 1 study of Breast Cancer that has completed, run by Bavarian Nordic. The registered enrollment target is 9 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00485277, a Phase 1 study of Breast Cancer, has completed, sponsored by Bavarian Nordic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 2
- Study locations
Study Summary
The current trial, BNIT-BR-002, will evaluate the safety and biological activity of a fixed dose of MVA-BN®-HER2, with and without Herceptin, following 1st- or 2nd-line chemotherapy in patients with Her-2-positive metastatic breast cancer. The intent of vaccination is to induce anti-Her-2 immune responses, both antibody and T cell, that will then attack the Her-2 expressing tumors, and may induce tumor regression or slow progression of disease.
Conditions Studied
Interventions
- BIOLOGICAL MVA-BN-HER2
Study Locations (2)
California
- Alta Bates Herrick Hospital Comprehensive Cancer Center - Berkeley
- Stanford Cancer Center - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2007-06 |
| Est. Completion | 2010-09 |
| Phase | Phase 1 |
What the finished NCT00485277 record still lists
NCT00485277 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which MVA-BN-HER2 is the first listed.
NCT00485277 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00485277 about?
NCT00485277 is a clinical study titled "A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer". The current trial, BNIT-BR-002, will evaluate the safety and biological activity of a fixed dose of MVA-BN®-HER2, with and without Herceptin, following 1st- or 2nd-line chemotherapy in patients with Her-2-positive metastatic breast cancer. The intent of vaccination is to induce anti-Her-2 immune re...
What is the current status of trial NCT00485277?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2007-06. Estimated completion is 2010-09.
What conditions does trial NCT00485277 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00485277?
The interventions under investigation include: MVA-BN-HER2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00485277?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00485277 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00485277's enrollment target sits among peer trials
9 1190th of 1224 higher than 30 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia